Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Period	PE Ratio
2017-12-31	N/A
2019-12-31	N/A
2020-12-31	-151.07
2021-12-31	-82.53
2022-12-31	-47.05
2023-12-31	645.82
2024-12-31	82.80

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KRYS	$258.33	-2.23%	0.23M
3
4
5

Krystal Biotech Inc. (KRYS) PE Ratio

PE Ratio Data

Get Krystal Biotech Inc. Data in Excel

More KRYS Financial Data